Biohaven PE Ratio 2016-2022 | BHVN

Current and historical p/e ratio for Biohaven (BHVN) from 2016 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biohaven PE ratio as of January 27, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biohaven PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-27 18.81 0.00
2022-09-30 151.17 $-13.94 0.00
2022-06-30 145.71 $-14.82 0.00
2022-03-31 118.57 $-11.84 0.00
2021-12-31 137.81 $-13.08 0.00
2021-09-30 138.91 $-13.69 0.00
2021-06-30 97.08 $-14.33 0.00
2021-03-31 68.35 $-14.18 0.00
2020-12-31 85.71 $-13.04 0.00
2020-09-30 65.01 $-12.27 0.00
2020-06-30 73.11 $-11.04 0.00
2020-03-31 34.03 $-12.63 0.00
2019-12-31 54.44 $-10.97 0.00
2019-09-30 41.72 $-9.46 0.00
2019-06-30 43.79 $-8.95 0.00
2019-03-31 51.47 $-5.29 0.00
2018-12-31 36.98 $-6.20 0.00
2018-09-30 37.55 $-5.61 0.00
2018-06-30 39.52 $-5.27 0.00
2018-03-31 25.76 $-6.04 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.264B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00